Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.64 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.60 |
| ▸ | TUBB | P07437 | 1/20 | 0.60 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.60 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.60 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.60 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16894651 | 0.88 | TUBB4A (0.76) | ABCB1ALDH1A1CYP3A4MAPTMAPK1 | |
| SCHEMBL29612043 | 0.84 | TERT (0.77) | ABCB1ALDH1A1CYP3A4MAPTMAPK1 | |
| SCHEMBL988001 | 0.84 | TERT (0.77) | ABCB1ALDH1A1CYP3A4MAPTMAPK1 | |
| SCHEMBL6613762 | 0.80 | ALDH1A1 (0.73) | ABCB1ALDH1A1CYP3A4MAPTMAPK1 | |
| Nobiletin SCHEMBL30049905 | 0.79 | ALDH1A1 (1.00) | ABCB1ALDH1A1CYP3A4MAPTMAPK1 | |
| Nobiletin SCHEMBL30049859 | 0.79 | ALDH1A1 (1.00) | ABCB1ALDH1A1CYP3A4MAPTMAPK1 | |
| Nobiletin SCHEMBL22092292 | 0.79 | ALDH1A1 (1.00) | ABCB1ALDH1A1CYP3A4MAPTMAPK1 | |
| Nobiletin SCHEMBL244029 | 0.79 | ALDH1A1 (1.00) | ABCB1ALDH1A1CYP3A4MAPTMAPK1 | |
| Nobiletin SCHEMBL29374681 | 0.79 | ALDH1A1 (1.00) | ABCB1ALDH1A1CYP3A4MAPTMAPK1 | |
| SCHEMBL13325112 | 0.79 | TUBB4A (0.73) | ABCB1ALDH1A1CYP3A4MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063665-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-01 | — | — | US | claimed |
| US-20020160983-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2002-10-31 | — | — | US | claimed |
| US-20040063665-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-01 | — | — | US | disclosed |
| US-20020160983-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160983-A1 | Substituted benzopyranones as telomerase inhibitors | TERT, TERF2, TERF2IP | ABCB1 704/4885ALDH1A1 1247/4885CYP3A4 3385/4885 |
| US-20040063665-A1 | Substituted benzopyranones as telomerase inhibitors | TERT, TERF2, TERF2IP | ABCB1 727/4885ALDH1A1 1265/4885CYP3A4 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.